文献速递甲状腺核医学核素与放射性配体治疗肿瘤 PET/CT

双示踪剂分子影像显示晚期甲状腺髓样癌肿瘤异质性:揭示SSTR与PSMA导向内放射治疗的诊疗潜力

Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy.
PubMed 文献 · Clin Nucl Med · 2022-01-27

本文报道一名60岁男性甲状腺髓样癌伴肝、骨及淋巴结转移患者,接受177Lu-DOTATOC肽受体放射性核素治疗2个周期后,68Ga-DOTATOC PET/CT显示多处病灶无摄取。为评估患者是否适合前列腺特异性膜抗原(PSMA)靶向放射性配体治疗,行PSMA PET/CT,发现68Ga-DOTATOC有摄取和无摄取病灶均显示PSMA表达增高。双放射性示踪剂PET/CT可能有助于了解甲状腺髓样癌患者肿瘤异质性的复杂性,并可能为后续治疗决策提供依据。

要点

  • 60岁男性甲状腺髓样癌伴肝、骨及淋巴结转移,接受177Lu-DOTATOC肽受体放射性核素治疗。
  • 2个周期后68Ga-DOTATOC PET/CT显示多处无摄取病灶。
  • PSMA PET/CT显示68Ga-DOTATOC有摄取和无摄取病灶均PSMA表达增高。

核心结论

  • 双放射性示踪剂PET/CT可能有助于了解甲状腺髓样癌患者肿瘤异质性的复杂性,并可能为后续治疗决策提供依据。

研究设计与样本

  • 病例报告:一名60岁男性甲状腺髓样癌伴肝、骨及淋巴结转移患者,接受177Lu-DOTATOC肽受体放射性核素治疗,2个周期后行68Ga-DOTATOC PET/CT,随后行PSMA PET/CT。

主要发现

  • 177Lu-DOTATOC治疗2个周期后,68Ga-DOTATOC PET/CT显示多处无摄取病灶。
  • PSMA PET/CT显示68Ga-DOTATOC有摄取病灶和无摄取病灶均PSMA表达增高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We present the case of a 60-year-old man with medullary thyroid carcinoma and hepatic, osseous, and lymph node metastases who underwent peptide receptor radionuclide therapy with 177Lu-DOTATOC. After 2 cycles, 68Ga-DOTATOC PET/CT revealed multiple nonavid lesions. To assess whether the patient would be eligible for prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, a PSMA PET/CT was conducted. PSMA PET/CT identified increased PSMA expression in both 68Ga-DOTATOC-avid and nonavid lesions. As such, dual-radiotracer PET/CT may allow for insights into the complexities of tumor heterogeneity in patients with medullary thyroid carcinoma, which may pave the way for subsequent therapeutic algorithms.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hasenauer N, Higuchi T, Deschler-Baier B, et al. Visualization of Tumor Heterogeneity in Advanced Medullary Thyroid Carcinoma by Dual-Tracer Molecular Imaging: Revealing the Theranostic Potential of SSTR- and PSMA-Directed Endoradiotherapy. Clin Nucl Med. 2022. PMID: 35085172. doi:10.1097/RLU.0000000000004082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。